2021 SITC: Comprehensive profiling of the tumor-immune microenvironment using an augmented transcriptome
Comprehensive profiling of both the tumor and tumor microenvironment (TME) can help further our
understanding of tumor progression and response to treatment. Many immune features can be extracted from transcriptomic data, including characterization of the immune infiltrate and profiling of the diversity of immune receptors. To address this, we have developed multiple TME profiling features as part of the ImmunoID NeXT Platform®, an augmented, immuno-oncology-optimized exome/transcriptome platform designed to provide comprehensive information regarding the tumor and TME from a single FFPE tumor sample. These features include quantification of immune cell infiltration and profiling of the T-cell receptor (TCR) and B-cell receptor (BCR).
Comprehensive tumor and immune profiling with the ImmunoID NeXT Platform
To address the challenge of providing characterization of both the tumor and TME, we have developed the ImmunoID NeXT Platform, an augmented, immuno-oncology-optimized exome/transcriptome platform designed to provide comprehensive information from a single FFPE tumor sample.